Skip to main content
Erschienen in: Medical Oncology 4/2011

01.12.2011 | Original Paper

Partial trisomy 11, dup(11)(q23q13), as a defect characterizing lymphomas with Burkitt pathomorphology without MYC gene rearrangement

verfasst von: Barbara Pienkowska-Grela, Grzegorz Rymkiewicz, Beata Grygalewicz, Renata Woroniecka, Paulina Krawczyk, Katarzyna Czyz-Domanska, Jan Walewski

Erschienen in: Medical Oncology | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

Burkitt lymphoma (BL) is an aggressive non-Hodgkin lymphoma characterized by specific morphological and immunophenotypic features. The basic genetic feature of BL is the rearrangement of MYC gene, visible as t(8;14)(q24;q32) translocation or its variant. However, some lymphomas with characteristic BL morphology are nowadays diagnosed as B-cell lymphoma unclassifiable with features intermediate between DLBCL and BL (Inter-DLBCL/BL) for biological or clinical reasons. We present four lymphomas without the MYC rearrangement presented typical Burkitt morphology, FCM immunophenotype with some deviations when compared to a typical BL. The cases were finally diagnosed as Inter-DLBCL/BL. All of them presented a recurrent abnormality within the chromosome 11: dup(11)(q23q13). We suppose that the dup(11)(q23q13), in absence of the MYC gene rearrangement, is connected with borderline lymphomas with a morphology similar or identical to that of the Burkitt lymphoma. Identifying such an aberration may be helpful in the diagnostics of Inter-DLBCL/BL eventually forming a distinct subgroup of lymphomas.
Literatur
1.
Zurück zum Zitat Dave SS, et al. Lymphoma/leukemia molecular profiling project. Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med. 2006;354:2431–42.PubMedCrossRef Dave SS, et al. Lymphoma/leukemia molecular profiling project. Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med. 2006;354:2431–42.PubMedCrossRef
2.
Zurück zum Zitat Kluin PM. B-cell lymphoma, unclassifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 265–6. Kluin PM. B-cell lymphoma, unclassifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 265–6.
3.
Zurück zum Zitat Leoncini L. Burkitt lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 262–4. Leoncini L. Burkitt lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008. p. 262–4.
4.
Zurück zum Zitat Sevilla DW, et al. Clinicopathologic findings in high-grade B-cell lymphomas with typical Burkitt morphologic features but lacking the MYC translocation. Am J Clin Pathol. 2007;128(6):981–91.PubMedCrossRef Sevilla DW, et al. Clinicopathologic findings in high-grade B-cell lymphomas with typical Burkitt morphologic features but lacking the MYC translocation. Am J Clin Pathol. 2007;128(6):981–91.PubMedCrossRef
5.
Zurück zum Zitat Harris NL, Horning SJ. Burkitt’s lymphoma—the message from microarrays. N Engl J Med. 2006;354:2495–8.PubMedCrossRef Harris NL, Horning SJ. Burkitt’s lymphoma—the message from microarrays. N Engl J Med. 2006;354:2495–8.PubMedCrossRef
6.
Zurück zum Zitat Patte C, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescent: it is possible to reduce treatment for the early responding patients. Blood. 2007;109:2773–80.PubMed Patte C, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescent: it is possible to reduce treatment for the early responding patients. Blood. 2007;109:2773–80.PubMed
7.
Zurück zum Zitat Margath IT, et al. An effective therapy for both undifferentiated (including Burkitt’s) lymphomas and lymphoblastic lymphomas in children and young adults. Blood. 1984;63:1102–11. Margath IT, et al. An effective therapy for both undifferentiated (including Burkitt’s) lymphomas and lymphoblastic lymphomas in children and young adults. Blood. 1984;63:1102–11.
8.
Zurück zum Zitat Diebold J, Jaffe ES, Raphael M, Warnke RA. Burkitt lymphoma. In: Jaffe E, Harris NL, Stein H, Vardiman JW, editors. Pathology and genetics: tumours of haematopoietic and lymphoid tumours. Lyon: AIARC Press; 2001. p. 181–4. Diebold J, Jaffe ES, Raphael M, Warnke RA. Burkitt lymphoma. In: Jaffe E, Harris NL, Stein H, Vardiman JW, editors. Pathology and genetics: tumours of haematopoietic and lymphoid tumours. Lyon: AIARC Press; 2001. p. 181–4.
9.
Zurück zum Zitat Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. Blood. 2004;104:3009–20.PubMedCrossRef Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. Blood. 2004;104:3009–20.PubMedCrossRef
10.
Zurück zum Zitat Hecht JL, Aster JC. Molecular biology of Burkitt’s lymphoma. J Clin Oncol. 2000;18:3707–21.PubMed Hecht JL, Aster JC. Molecular biology of Burkitt’s lymphoma. J Clin Oncol. 2000;18:3707–21.PubMed
11.
Zurück zum Zitat Chan NP, Ma ES, Wan TS, Chan LC. The spectrum of acute lymphoblastic leukemia with mature B-cell phenotype. Leuk Res. 2003;27:231–4.PubMedCrossRef Chan NP, Ma ES, Wan TS, Chan LC. The spectrum of acute lymphoblastic leukemia with mature B-cell phenotype. Leuk Res. 2003;27:231–4.PubMedCrossRef
13.
Zurück zum Zitat Hummel M, Bentink S, Berger H. A biological definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354:2419–30.PubMedCrossRef Hummel M, Bentink S, Berger H. A biological definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N Engl J Med. 2006;354:2419–30.PubMedCrossRef
14.
Zurück zum Zitat Shaffer LG, Tommerup N, editors. ISCN: an international system for human cytogenetic nomenclature. Basel: S. Karger; 2005. Shaffer LG, Tommerup N, editors. ISCN: an international system for human cytogenetic nomenclature. Basel: S. Karger; 2005.
16.
Zurück zum Zitat Koduru PRK, Offit K, Jhanwar SC. Molecular analysis of structural chromosome changes affecting chromosome band 11q23. Dis Markers. 1989;7:145–52.PubMed Koduru PRK, Offit K, Jhanwar SC. Molecular analysis of structural chromosome changes affecting chromosome band 11q23. Dis Markers. 1989;7:145–52.PubMed
17.
Zurück zum Zitat Leucci E, et al. MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation. J Pathol. 2008;216:440–50.PubMedCrossRef Leucci E, et al. MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation. J Pathol. 2008;216:440–50.PubMedCrossRef
18.
Zurück zum Zitat Jerkeman M, et al. Prognostic implication of cytogenetic aberrations in diffuse large B-cell lymphomas. Eur J Haematol. 1999;62:184–90.PubMedCrossRef Jerkeman M, et al. Prognostic implication of cytogenetic aberrations in diffuse large B-cell lymphomas. Eur J Haematol. 1999;62:184–90.PubMedCrossRef
19.
Zurück zum Zitat Espinet B, Florensa L, Salido M, Solé F. MLL intrachromosomal amplification in a pre-B acute lymphoblastic leukemia. Haematologica. 2003;88(2):EIM03.PubMed Espinet B, Florensa L, Salido M, Solé F. MLL intrachromosomal amplification in a pre-B acute lymphoblastic leukemia. Haematologica. 2003;88(2):EIM03.PubMed
20.
Zurück zum Zitat Deisch J, et al. Segmental tandem triplication of the MLL gene in an intravascular large B-cell lymphoma with multisystem involvement: a comprehensive morphologic, immunophenotypic, cytogenetic, and molecular cytogenetic antemortem study. Arch Pathol Lab Med. 2009;133(9):1477–82.PubMed Deisch J, et al. Segmental tandem triplication of the MLL gene in an intravascular large B-cell lymphoma with multisystem involvement: a comprehensive morphologic, immunophenotypic, cytogenetic, and molecular cytogenetic antemortem study. Arch Pathol Lab Med. 2009;133(9):1477–82.PubMed
Metadaten
Titel
Partial trisomy 11, dup(11)(q23q13), as a defect characterizing lymphomas with Burkitt pathomorphology without MYC gene rearrangement
verfasst von
Barbara Pienkowska-Grela
Grzegorz Rymkiewicz
Beata Grygalewicz
Renata Woroniecka
Paulina Krawczyk
Katarzyna Czyz-Domanska
Jan Walewski
Publikationsdatum
01.12.2011
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 4/2011
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9614-0

Weitere Artikel der Ausgabe 4/2011

Medical Oncology 4/2011 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.